CAJ | 학술논문

目的：探讨Ⅱ~Ⅲ期肺腺癌（lung adenocarcinoma）患者体内Bcl-2和Beclin-1基因、蛋白表达与新辅助化疗间关系。方法：经免疫组织化学法检测Ⅱ~Ⅲ期肺腺癌80例患者组织中Bcl-2和Beclin-1蛋白表达水平，利用实时定量聚合酶链反应法检测治疗后Ⅱ~Ⅲ期肺腺癌患者组织中Bcl-2和Beclin-1基因表达水平，并研究2种基因表达与新辅助化疗疗效间关系。结果：治疗前两组之间Bcl-2和Beclin-1的蛋白表达水平差异无统计学意义，且Beclin 1与Bcl-2在肺腺癌中表达呈负相关，其相关性具有统计学意义（r=-0.43，P<0.01）。实时定量聚合酶链反应法检测结果显示经新辅助化疗后，化疗组Beclin-1 mRNA水平明显高于对照组，而Bcl-2水平明显低于对照组，治疗前恰恰相反，差异有统计学意义（P<0.05）。结论：利用新辅助顺铂和多西他赛方案术前化疗，可影响肺腺癌组织中Bcl-2和Beclin-1的表达水平，为研究抑制Bcl-2的表达提高临床参考。
목적：탐토Ⅱ~Ⅲ기폐선암（lung adenocarcinoma）환자체내Bcl-2화Beclin-1기인、단백표체여신보조화료간관계。방법：경면역조직화학법검측Ⅱ~Ⅲ기폐선암80례환자조직중Bcl-2화Beclin-1단백표체수평，이용실시정량취합매련반응법검측치료후Ⅱ~Ⅲ기폐선암환자조직중Bcl-2화Beclin-1기인표체수평，병연구2충기인표체여신보조화료료효간관계。결과：치료전량조지간Bcl-2화Beclin-1적단백표체수평차이무통계학의의，차Beclin 1여Bcl-2재폐선암중표체정부상관，기상관성구유통계학의의（r=-0.43，P<0.01）。실시정량취합매련반응법검측결과현시경신보조화료후，화료조Beclin-1 mRNA수평명현고우대조조，이Bcl-2수평명현저우대조조，치료전흡흡상반，차이유통계학의의（P<0.05）。결론：이용신보조순박화다서타새방안술전화료，가영향폐선암조직중Bcl-2화Beclin-1적표체수평，위연구억제Bcl-2적표체제고림상삼고。
Objective:To investigate the expressions of Bcl-2 gene and Beclin-1 gene and the efficacy of neoadju-vant chemotherapy in patients with stage II-III lung adenocarcinoma. Methods:Eighty patients with stageⅡ-Ⅲlung ade-nocarcinoma were randomly divided into two groups and were enrolled in the study before chemotherapy:one group accept-ed operation treatment after two weeks of neoadjuvant chemotherapy;the another directly accepted operation treatment.The expression of Bcl-2 and Beclin-1 were detected bv immunohistochemistry before chemotherapy and the correlation of the expression of Bcl-2 and Beclin-1 the response rate of chemotherapy was analyzed. The mRNA expression of Bcl-2 and Beclin-1 were measuerd by realtime-PCR after neoadjuvant chemotherapy. The relationship between the two groups and the change of the gene expression levels under the impact of neoadjuvant chemotherapy was studied. Result:There was no difference in Bcl-2 and Beclin-1 protein expression between the groups before chemotherapy,and was negatively correlated between Beclin 1 and Bcl-2 expression levels in lung adenocarcinoma (r=-0.43, P<0.001). It was showed that Bcl-2 and Beclin-1 mRNA levels were significantly different after neoadjuvant chemotherapy by realtime PCR.The results showed that the mRNA levels of Beclin-1 expression were significantly higher in chemotheroapy group than control group while the ex-pression of Bcl-2 decreased.The gene expression levels were the significant difference between the two groups (P<0.05). Conclusion: The data indicated that neoadjuvant chemotherapy might influence the expressions of Bcl-2 and Beclin-1 in lung adenocarcinoma and provide clinical reference for the inhibition of Bcl-2 expression.